Background. In nonhealthcare settings, widespread screening for acute human immunodeficiency virus (HIV) infection (AHI) is limited by cost and decision algorithms to better prioritize use of resources. Comparative cost analyses for available strategies are lacking.
Ambitious recommendations for universal human immunodeficiency virus (HIV) testing in the United States are supported by observations that HIV diagnoses are frequently linked to reduced sexual risk behaviors and earlier uptake of antiretroviral therapy, both of which are expected to result in decreased HIV transmission [1] [2] [3] [4] . Diagnosis of HIV infection during the acute stage of infection is especially important since transient levels of extremely high titer HIV RNA during acute HIV infection (AHI) are associated with rapid immune destruction and significantly greater infectivity than during chronic infection [5, 6] .
The recognition that persons with AHI contribute disproportionately to population-level HIV transmission supports the updated recommendations for laboratory diagnosis of HIV infection in healthcare settings that use fourth-generation immunoassays to detect HIV-1/HIV-2 antibody (Ab) and HIV-1 p24 antigen (Ag) to detect AHI [7] . Detection of p24 Ag by the ARCHITECT Ag/Ab Combo assay is currently the most widely used approach for detecting AHI [8] [9] [10] [11] [12] [13] . Alternative approaches for detecting and differentiating p24 Ag and HIV Ab include the rapid Alere Determine HIV-1/2 Combo assay and more sensitive HIV-1 nucleic acid amplification tests (NATs) [14, 15] .
While AHI screening in healthcare settings is now recommended, one might wonder whether routine AHI screening should be the standard of care in community HIV screening programs, where about 40% of new HIV infections are diagnosed in the United States [16] . The main deterrents of widespread use of community HIV screening algorithms to detect AHI appear to be the elevated costs, need for venipuncture, concerns about turnaround time, and lack of laboratory capacity [6, [17] [18] [19] . Absence of point-of-care (POC) tests that reliably detect AHI may be the major cost-contributing factor, as AHI screening strategies in community-based settings frequently require second visits or alternative approaches to inform clients of their test results. However, detailed cost analyses to compare testing strategies that identify acutely HIV-infected (ie, before seroconversion) and nonacutely HIV-infected (ie, after seroconversion) persons have not been performed. Therefore, there is uncertainty about the HIV prevalence rate needed to justify the cost of these testing algorithms compared with strategies that rely on POC HIV Ab testing only.
We developed and evaluated the first economic model to estimate the annual cost of a community-based AHI screening algorithm that consists of POC Ab plus individual donation qualitative NAT (ID-NAT; ie, the EarlyTest algorithm, I). We compared EarlyTest to 2 p24 Ag-based algorithms that detect AHI by either using Architect (II) or Determine (III). We further compared costs of these algorithms to an algorithm that relies on Ab testing alone (Antibody, IV).
MATERIAL AND METHODS
The 1-year cost analyses were conducted using an established HIV testing program perspective. The cost model was based on numbers of tests per year in men who have sex with men (MSM) who enrolled in the EarlyTest HIV screening program for the San Diego Primary Infection Resource Consortium (SD PIRC) between 2006 and 2014. There were 3000 HIV tests performed per year, resulting in an overall prevalence of 2.9% (n = 87) newly diagnosed HIV infections (0.7% [n = 21] with AHI and 2.2% (n = 66) with established infection). Participants were MSM who reported sexual contact with men during the 12 months prior to testing. Basic demographics, risk behaviors, and frequency of repeat HIV testing from this cohort have been published previously [20] [21] [22] . An estimated date of infection was calculated for all recently infected persons using previously published criteria for serologic and virologic test results [23] . AHI was defined as having a negative HIV Ab test in the presence of detectable HIV-1 RNA (ie, Fiebig stages I-II), with an estimated date of infection within the last 10 days [24] .
Algorithms
Annual costs were calculated for the year 2014 for the EarlyTest algorithm (ie, algorithm I) that includes POC HIV-1 Ab testing (INSTI HIV-1 Antibody Test, bioLytical Laboratories Inc., Richmond, Canada) [25] followed by ID-NAT (Procleix Ultrio, Hologic, Bedford, Massachusetts) in all individuals with negative or invalid POC test results. Study participants were notified of positive HIV NAT results approximately 4 days after their Ab test. We then compared costs to those estimated for an alternative testing algorithm (ie, algorithm II) that included POC HIV-1 Ab testing (INSTI) followed by Architect HIV Ag/Ab Combo (Abbott Diagnostics, Abbott Park, Illinois), that is, the Architect algorithm. We also compared costs of the EarlyTest and Architect algorithms to estimated costs of 2 rapid/POC algorithms: algorithm III, using the Determine HIV-1/2 Ag/Ab Combo test (Alere Inc, Waltham, Massachusetts; Determine algorithm), and algorithm IV, using POC HIV Ab testing (INSTI) alone (Antibody algorithm). All 4 algorithms are shown in Figure 1 .
Performance calculations were carried out for all tests used in this cost analysis. Sensitivity of the Procleix Ultrio assay for HIV virus detection is 100% at 300 copies/mL and 99% at 100 copies/mL [26] . Summarizing previous studies, sensitivity of the Architect assay for seronegative AHI is 80% (n = 143/178 of samples positive; 95% confidence interval [CI], 74%-86%) [8-13, 27, 28] , while sensitivity of the Determine combo is 50% (n = 51/102 samples positive; 95% CI, 40%-60%) [8, [29] [30] [31] [32] . Specificities of the tests for HIV infection are listed in Supplementary Table 1 . In algorithms that do not provide POCpositive results for AHI (ie, EarlyTest and Architect), a 5% (95% CI, 1%-9%) loss to follow-up (ie, clients not informed about AHI diagnosis) was estimated.
Costs per Test Results
The cost model was based on work-time estimates and compensation in the EarlyTest HIV screening program, San Diego. Results are expressed in 2014 US dollars. Details on calculations of cost per negative test result, established HIV diagnosis, and AHI diagnosis using the different algorithms are included in the Supplementary Materials.
Cost Thresholds
Calculated thresholds for cost-savings (ie, $22 909) and costeffectiveness (ie, $63 053) per new HIV diagnosis derived by Farnham and colleagues were the basis for thresholds used in this study [33] . As those costs were calculated in 2009 US dollars, the thresholds were updated to 2014 US dollars by adding the cumulative rate of inflation (ie, 10.3%). This resulted in a cost-savings threshold of $25 269 and a cost-effectiveness threshold of $69 547. We therefore hypothesized that the incremental cost-effectiveness ratio (ICER) of EarlyTest in a population of MSM undergoing community-based HIV screening will be less than $25 269 per diagnosis of seronegative AHI when compared with the 3 alternative algorithms.
Incremental Cost-Effectiveness Ratios per AHI
ICERs were calculated by comparing 2 testing algorithms, with the numerator representing the differences in annual costs of the 2 algorithms and the denominator representing the difference in numbers of annual AHI diagnoses. Details are depicted in the supplement. ICERs were calculated for numbers of tests per year and prevalence of HIV and AHI in MSM who enrolled in the EarlyTest and SD PIRC between 2006 and 2014.
Sensitivity Analyses
We performed a 2-way sensitivity analysis by calculating ICERs per AHI for HIV prevalence rates that were less than those observed in the SD PIRC (range, 0.001-0.029) and 2 proportions of AHI (0.24 and 0.10 of all HIV diagnoses). While AHI cases represented 24% of all newly diagnosed HIV cases among MSM in the SD PIRC, a lower proportion of 10% may be more appropriate for settings in which clients undergo screening more infrequently [34, 35] .
We also assessed the effect of a number of alternate plausible assumptions and used a probabilistic sensitivity analysis (PSA) to examine the impact of cost parameter uncertainty. For the PSA, we assigned uniformly distributed 95% CIs to applicable cost items (ie, all cost items except items that showed no variation, such as costs of tests, which were given by the manufacturer or represent actual costs in our setting, or salary; depicted in Table 1 ). To account for uncertainty in test sensitivities, we assigned normally distributed 95% CIs to AHI sensitivities of the Architect and Determine combo (ie, test performances were calculated using previous studies and tests; in contrast to ID-NAT, Architect and Determine were not routinely performed in the SD PIRC setting), as well as for loss to follow-up in algorithms that do not provide POC-positive results for AHI (ie, EarlyTest and Architect; all 95% CIs are listed in the algorithm paragraph of the Methods section). As specificities of all the evaluated tests are high (>99%) and 95% CIs are very small (due to the large number of HIV-negative samples tested previously), impact of specificity uncertainty on the cost model was shown to be minimal (details in Supplementary Material); therefore, we did not include 95% CIs for specificities into the PSA. To determine the frequency at which each algorithm was cost-saving/cost-effective at the given thresholds, we conducted Monte Carlo simulations to obtain 1000 samples from all distributions and used these samples to calculate means and 95% CIs for ICERs per AHI by using the 2.9% HIV prevalence rate and AHI proportions of 24% and 10%. We also used PSA to calculate ICERs for the lower 95% CIs of the sensitivity of the Determine combo in AHI samples (ie, 40% sensitivity). Table 1 . Estimated total annual costs associated with each algorithm using the SD PIRC MSM model (with 3000 annual HIV tests) are displayed in Figure 2 (for more detailed information, see Supplementary Table 2 ).
RESULTS

Cost items (including 95% CIs) as well as costs per test result in the 4 testing algorithms are depicted in
Incremental Cost-Effectiveness Ratio per AHI: Base Model
Costs per acute HIV diagnosis (ie, ICER), determined by comparing each 2 of the 4 testing algorithms, are depicted in Figure 2 . AHI was detected in 21 individuals using the EarlyTest algorithm, and 5% of those were lost to follow-up. Based on a lower sensitivity of Architect (80%) compared with the Procleix Ultrio (markedly over 99%), 3.99 of these diagnoses would be missed by the Architect ("false-negative" result). These 3.99 cases of AHI are diagnosed only with EarlyTest, with an excess cost of $8764 when compared with Architect. The ICER of Ear-lyTest relative to Architect therefore is $2196 per AHI diagnosis (ie, $8764 divided by 3.99). ICERs per AHI diagnosis for Ear-lyTest compared with Determine (III) and for the 3 algorithms that detect AHI (ie, EarlyTest, Architect, and Determine) compared with Antibody (IV) alone are displayed in Table 2 and Figure 2 . EarlyTest was cost-savings compared with the other 3 algorithms, Architect was cost-savings when compared with Determine (ICER $14,776.50) and Antibody, and Determine was cost-savings when compared with Antibody [36] . ICERs per AHI when assuming a lower proportion of AHI cases (10% of all new HIV diagnoses) are depicted in Table 2 .
Model for Community-based Screening Programs With Lower HIV Prevalence/2-way Sensitivity Analyses
Comparing all 4 algorithms and assuming a 24% rate of AHI among all HIV diagnoses, EarlyTest was cost-effective (ie, ICER per AHI less than $69 547) for HIV prevalence rates >0.4%. Determine was cost-effective for prevalence rates between 0.1% and 0.4%. For ≤0.1% HIV prevalence, none of the 3 algorithms that detect AHI was cost-effective compared with Antibody alone (Figure 3) . Architect was cost-effective when compared with Determine for HIV prevalence rates >0.6%. ICERs for AHI per HIV prevalence rates assuming a 10% rate of AHI among HIV diagnoses (ie, more applicable for other populations with less frequent screening) are depicted in Figure 3C and 3D . EarlyTest was cost-effective compared with the 3 other algorithms for HIV prevalence rates ≥1.0%. Determine was cost-effective for prevalence rates between ≥0.3% and 1.0%; below 0.3% HIV prevalence, none of the 3 algorithms that detect AHI was cost-effective compared with Antibody alone. When compared with Determine, Architect was cost-effective for HIV prevalence rates >1.5%.
Probabilistic Sensitivity Analysis
Results of the PSA for a 2.9% HIV prevalence with AHI proportions of 24% and 10%, including standard deviations, are listed in Table 2 (including ICERs calculated for the lower 95% CI of the Determine combo). EarlyTest compared favorably (ie, was below the ICER per AHI cost-effectiveness threshold) 100% of the time compared with the other 3 algorithms for both proportions of AHI. Architect and Determine were cost-effective 100% of the time compared with Antibody only. Finally, Architect was cost-effective compared with Determine 100% of the time at an AHI proportion of 24%, and 99% of the time at a proportion of 10%. 
DISCUSSION
We conducted a cost analysis of the EarlyTest communitybased HIV screening approach (ie, POC Ab plus routine ID-NAT in Ab-negative persons) and found that this approach was cost-savings (ie, ICERs less than $13.000 per AHI diagnosis) among a cohort of MSM when compared with 3 alternative testing strategies (using p24 Ag/HIV Ab detection and/or POC Ab alone). While cost-savings and cost-effectiveness cutoffs used in this study were calculations from a previous mathematical model [33] , other cutoffs on the costs to be paid per AHI diagnosis have yet to be defined. Diagnosis of HIV at acute stages followed by appropriate interventions to prevent further transmission may be a highly effective biomedical HIV prevention strategy [1, 37] . Cost models are critical for establishing the cost-effectiveness of community-based AHI screening, particularly given the additional costs associated with these screening methods. Here, we demonstrate that AHI screening is cost-effective among a metropolitan population of MSM.
The cost-effectiveness of using both that POC Ab test and quantitative NAT (with prompt initiation of antiretroviral treatment in those identified with HIV infection) when compared with HIV-Ab testing alone has been reported for persons who inject drugs while undergoing HIV screening every 3-6 months [38] . The routine addition of quantitative viral load testing for all annual HIV tests in MSM, however, has been estimated to increase the cost of screening by more than $100 000 per quality-adjusted life year gained [39] . Our results indicate that "cheaper" qualitative ID-NAT may provide an alternative cost-effective community-based screening technology for AHI in similar populations of MSM with an HIV prevalence >0.4%. The potential detection of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in persons at risk for HIV represents an additional benefit of the EarlyTest algorithm, as the Procleix Ultrio assay, which is used for HIV NAT screening, may also detect proportions of HBV and HCV infections [14, 15] .
In our MSM model, EarlyTest compared favorably with the 2 other AHI algorithms based on p24 Ag detection. Similar to ID-NAT, Architect, even when performed "in house," did not deliver POC results, and total costs of Architect therefore resembled those of the EarlyTest algorithm. The lower sensitivity of Architect for AHI compared with ID-NAT led to an unfavorable cost-effectiveness for Architect when compared with Ear-lyTest. Nevertheless, Architect compared favorably with Determine in settings with HIV prevalence >0.6%. Therefore, Architect may be a promising testing strategy in settings where it is readily available and ID-NAT is more expensive, especially because Architect may deliver results more rapidly than ID-NAT (ie, typically within 1 day).
In contrast, costs of the rapid Determine algorithm were markedly lower than those of EarlyTest. Cost items of Determine were similar to those for Antibody alone, with the major difference being that the Determine test may also detect some cases of AHI. While sensitivity of the Determine combo for AHI detection is disappointing, Determine may nevertheless represent a cost-effective alternative to community-based screening algorithms that use POC Antibody alone. This is true, in particular, for settings where limited resources may preclude use of ID-NAT or Architect screening and where there are populations with lower HIV prevalence rates. However, it has to be mentioned that sensitivities of the Determine test for AHI vary widely, with higher sensitivities found in frozen samples and even lower sensitivities in studies that evaluated real-life use [31, 32] . By assuming a 50% sensitivity of the test, which was calculated over all the studies (frozen samples and real life), our model suggests that Determine may be the only AHI screening algorithm that is cost-effective for very low HIV prevalence rates between 0.1% and 0.4% (ie, below the national average of 0.6% found in the United States).
Our study has several limitations. First, thresholds for defining cost-effectiveness and cost-savings relied on calculations from a previous cost model and may be subject to change. Also, calculations were based on 3000 tests per year, with proportions of 24% and 10% among all newly diagnosed HIV cases, being diagnosed at acute stage of infection (ie, AHI). The magnitude of effects will vary in other settings with differing numbers of annual tests and proportion of AHI diagnoses, although the qualitative result that EarlyTest is cost-effective for higher HIV prevalence rates is likely to hold over a wide range of parameter values. Further, cost items used to calculate costs of the algorithms may not reflect actual costs at other locations, especially in countries other than the United States. For these reasons, results are likely to differ in settings were NAT testing is much more expensive and the proportion of AHI diagnoses is ≤5%. As the model was limited to a 1-year time horizon, longterm cost-effectiveness was not assessed. Also, although we tried our best to estimate cost, the ultimate costs of fourth-generation HIV testing using Determine and Architect in a real-world setting are unknown. Finally, our model was based on an established HIV testing program (ie, infrastructure in place) and does not include the costs of program development.
In conclusion, community-based screening programs that use EarlyTest and Architect are associated with higher direct annual costs compared with programs that rely on POC testing only. Although more expensive, early identification of HIV infection using the dual EarlyTest screening algorithm may markedly reduce HIV transmission rates and, considering earlier models, is likely to be cost-effective not only among at-risk MSM in San Diego but also among other similar populations of MSM with HIV prevalence rates >0.4%. The Architect algorithm may be the second-best alternative for HIV prevalence rates ≥0.6%, while the Determine and Antibody algorithms may be promising only for HIV prevalence rates below the national average or for screening programs among populations that are tested less frequently and are therefore more likely to be diagnosed at the stage of established HIV infection.
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